As­traZeneca chief Pas­cal So­ri­ot her­alds the start of a 'pe­ri­od of sus­tained growth for years to come'

As­traZeneca CEO Pas­cal So­ri­ot de­clared vic­to­ry to­day in the long-run­ning fight to turn around the strug­gling phar­ma gi­ant, gain­ing a sig­nif­i­cant spurt in Q3 sales for the com­pa­ny and point­ing to a pe­ri­od of “sus­tained growth” dri­ven by new prod­uct de­vel­op­ment, a strong com­mer­cial or­ga­ni­za­tion and suc­cess in the grow­ing Chi­na drug mar­ket.

Yes, rev­enue slid 14%, large­ly as a re­sult of a lull in the kind of ag­gres­sive “ex­ter­nal­iza­tion” from its drug port­fo­lio that has buoyed the com­pa­ny for years. But with its big 3 can­cer drugs — Lyn­parza, Tagris­so and now Imfinzi — lead­ing the way, the com­pa­ny has a work­able strat­e­gy to keep ex­pand­ing sales. That starts with a 9% in­crease in Q3 while year-to-date there’s been a 2% growth in this col­umn.

By any stan­dard, that is a ma­jor achieve­ment for the com­pa­ny and the ex­ec­u­tive crew in charge. And they $AZN would agree with that.

“To­day marks an im­por­tant day for the fu­ture of As­traZeneca,” So­ri­ot not­ed at the top of to­day’s re­lease, “with the per­for­mance in the quar­ter and year to date show­ing what we ex­pect will be the start of a pe­ri­od of sus­tained growth for years to come. Com­mer­cial ex­e­cu­tion has been ex­cep­tion­al and our new med­i­cines are now firm­ly es­tab­lished as the dri­vers of growth, sup­port­ing our con­tin­ued suc­cess in emerg­ing mar­kets.”

Of all the Big Phar­ma com­pa­nies, As­traZeneca has suf­fered some of the worst loss­es due to gener­ic com­pe­ti­tion for their old fran­chise drugs. That left So­ri­ot bat­ting away a takeover at­tempt by Pfiz­er as he worked to build a new foun­da­tion of drugs that can de­liv­er steadi­ly ris­ing, block­buster re­turns. 

Key to the process was gain­ing an ear­ly, break­through ap­proval for their PARP Lyn­parza, while go­ing on to build new rev­enue by adding sup­ple­men­tal ap­provals. Three more PARPs have now crowd­ed in be­hind As­traZeneca, but the UK com­pa­ny clear­ly has a com­mand­ing lead there. Through its multi­bil­lion-dol­lar part­ner­ship at Mer­ck, As­traZeneca is now in po­si­tion to book hun­dreds of mil­lions in added pay­ments in Q4’s ex­ter­nal­iza­tion col­umn — an­oth­er near term coup.

Tagris­so and Imfinzi, its PD-L1 drug, are both be­ing po­si­tioned for new growth based on clin­i­cal tri­al suc­cess­es. We still haven’t heard about the sec­ond big hur­dle for Imfinzi’s MYS­TIC study, which failed the first goal. But As­traZeneca’s out­line on its growth plans in­cludes a Q4 reg­u­la­to­ry fil­ing — though that out­come has been dis­count­ed now that the PA­CIF­IC study has come through to open up a sig­nif­i­cant new can­cer mar­ket for the com­pa­ny.

Sev­er­al of So­ri­ot’s strate­gies around new prod­uct de­vel­op­ment and sell­ing off as­sets — in­clud­ing but not lim­it­ed to mar­gin­al or dis­ap­point­ing prod­ucts — is fo­cused around the prin­ci­ple that the com­pa­ny need­ed to sim­pli­fy its ap­proach, con­cen­trat­ing on block­buster, stan­dard-of-care as­sets that could make a ma­jor dif­fer­ence. As­traZeneca un­der­scored that with a 6% drop in R&D ex­pens­es in Q3, even as the com­pa­ny con­tin­ues to pur­sue some big out­comes. And its ros­ter of drugs to watch in­cludes their asth­ma drug teze­pelum­ab, which has shown some re­al promise in treat­ing se­vere asth­ma.

At the same time, the phar­ma gi­ant con­tin­ues to win­now out the weak­est drugs from the pipeline.

Two months ago re­searchers bull­ish­ly out­lined the ef­fec­tive­ness of an As­traZeneca drug called vis­tusert­ib com­bined with chemo in treat­ing drug-re­sis­tant cas­es of ovar­i­an and lung can­cer. But in their pipeline up­date to­day the com­pa­ny not­ed it is re­mov­ing the mTOR in­hibitor from Phase II while al­so ax­ing an ear­ly-stage com­bo study with Calquence.

As­traZeneca has had plen­ty of set­backs along the way, and will cer­tain­ly have more to come. But while skep­tics will con­tin­ue to chal­lenge the com­pa­ny on rev­enue and over­all per­for­mance, you can’t ig­nore the im­por­tant achieve­ment So­ri­ot is point­ing to to­day.


Im­age: Pas­cal So­ri­ot. AP IM­AGES

Secretary of health and human services Alex Azar speaking in the Rose Garden at the White House (Photo: AFP)

Trump’s HHS claims ab­solute au­thor­i­ty over the FDA, clear­ing path to a vac­cine EUA

The top career staff at the FDA has vowed not to let politics overrule science when looking at vaccine data this fall. But Alex Azar, who happens to be their boss’s boss, apparently won’t even give them a chance to stand in the way.

In a new memorandum issued Tuesday last week, the HHS chief stripped the FDA and other health agencies under his purview of their rule making ability, asserting all such power “is reserved to the Secretary.” Sheila Kaplan of the New York Times first obtained and reported the details of the September 15 bulletin.

Two wild weeks for Grail end in $8B Il­lu­mi­na buy­out

Grail’s whirlwind two weeks have ended in the wealthy arms of its former founder and benefactors.

Illumina has shelled out $8 billion to reacquire the closely-watched liquid biopsy startup they spun out just 5 years ago and sold off much of its shares just 3 years ago. The deal comes nearly two weeks after the well-heeled startup filed for a potentially massive IPO — one that was disrupted just a week later when Bloomberg reported that Illumina was in talks to buy their former spinout for up to $8 billion.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 90,400+ biopharma pros reading Endpoints daily — and it's free.

#ES­MO20: 'As good as any PD-1 out there': Re­gen­eron flash­es PD-(L)1 lung can­cer da­ta to ri­val Mer­ck

Regeneron entered the PD-(L)1 game late, so they devised a two-pronged strategy to catch up with Big Pharma rivals: They would push it into cancers where PD-1s had yet been tested, and they would prove that it’s as powerful in the big indications as any other on the market.

They cleared a hurdle on the first goal Friday, showing a 31% response in patients with the rare skin cancer basal cell carcinoma. And with the data they’re rolling out Monday, Regeneron cancer chief Israel Lowy is ready to declare success on the second.

Roche vaults to the front of the NL­RP3 clin­i­cal race, pay­ing $448M up­front to bag In­fla­zome

Roche is going all in on NLRP3.

The pharma giant is putting down $448 million (€380 million) upfront to snatch Novartis-backed Inflazome, which makes it a clinical player in the space overnight.

Dublin and Cambridge, UK-based Inflazome is the second NLRP3-focused biotech Roche has acquired in less than two years, and although no numbers were disclosed in the Jecure buyout, this is almost certainly a much larger deal.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 90,400+ biopharma pros reading Endpoints daily — and it's free.

As­traZeneca pub­lish­es Covid-19 vac­cine PhI­II pro­to­cols in lock­step with Mod­er­na and Pfiz­er. How are they dif­fer­ent?

Following in the steps of Moderna and Pfizer, the other two American drugmakers currently in Phase III trials for their Covid-19 vaccines, AstraZeneca posted its own study protocols over the weekend. The move is the latest in a series of rare peeks behind the curtain, as such blueprints are typically shared once such trials are completed.

“Given the unprecedented global impact of the Coronavirus pandemic and the need for public information, AstraZeneca has published the detailed protocol and design of our AZD1222 clinical trial. As with most clinical development, protocols are not typically shared publicly due to the importance of maintaining confidentiality and integrity of trials. AstraZeneca continues to work with industry peers to ensure a consistent approach to sharing timely clinical trial information,” the company said in a statement.

Donald Trump and White House chief of staff Mark Meadows, before boarding Marine One (Getty Images)

Pric­ing deal col­laps­es over Big Phar­ma's re­fusal to is­sue $100 'cash card­s' be­fore the elec­tion — re­port

Late in August, as negotiations on a pricing deal with President Trump reached a boiling point, PhRMA president Stephen Ubl sent an email update to the 34 biopharma chiefs that sit on his board. He wrote that if the industry did not agree to pay for a $100 “cash card” sent to seniors before November, White House chief of staff Mark Meadows was going to tell the news media Big Pharma was refusing to “share the savings” with the elderly — and that all of the blame for failed drug pricing negotiations would lie squarely on the industry.

#ES­MO20: As­traZeneca aims to spur PRO­found shift in prostate can­cer treat­ment with Lyn­parza OS da­ta

AstraZeneca has unveiled the final, mature overall survival data that cemented Lynparza’s first approval in prostate cancer approval — touting its lead against rivals with the only PARP inhibitor to have demonstrated such benefit.

But getting the Merck-partnered drug to the right patients remains a challenge, something the companies are hoping to change with the new data cut.

The OS numbers on the subgroup with BRCA1/2 or ATM-mutated metastatic castration-resistant prostate cancer are similar to the first look on offer when the FDA expanded the label in May: Lynparza reduced the risk of death by 31% versus Xtandi and Zytiga. Patients on Lynparza lived a median of 19.1 months, compared to 14.7 months for the anti-androgen therapies (p = 0.0175).

Eli Lilly CSO Dan Skovronsky (file photo)

UP­DAT­ED: #ES­MO20: Eli Lil­ly shows off the da­ta for its Verzenio suc­cess. Was it worth $18 bil­lion?

The press release alone, devoid of any number except for the size of the trial, added nearly $20 billion to Eli Lilly’s market cap back in June. Now investors and oncologists will get to see if the data live up to the hype.

On Sunday at ESMO, Eli Lilly announced the full results for its Phase III MonarchE trial of Verzenio, showing that across over 5,000 women who had had HR+, HER2- breast cancer, the drug reduced the odds of recurrence by 25%. That meant 7.8% of the patients on the drug arm saw their cancers return within 2 years, compared with 11.3% on the placebo arm.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 90,400+ biopharma pros reading Endpoints daily — and it's free.

Sebastian Nijman (file photo)

Roche looks to ge­net­ic mod­i­fiers for new drug tar­gets, team­ing up with Dutch biotech in $375M deal

Roche is gambling on a new way of discovering drug targets and, ultimately, promising to infuse more than $375 million into a small biotech if all goes well.

A spinout of the Netherlands Cancer Institute and Oxford University, Scenic Biotech set out to pioneer a field that’s gaining some traction among top VCs in the US: to harness the natural protecting powers of genetic modifiers — specific genes that suppress a disease phenotype.